JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 39 No. 10 1810-1813
© 1998 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Owunwanne, A.
Right arrow Articles by Gopinath, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Owunwanne, A.
Right arrow Articles by Gopinath, S.

Placental Binding and Transfer of Radiopharmaceuticals: Technetium-99m d, 1-HMPAO

Azu Owunwanne, Alexander Omu, Mohan Patel, Mercy Mathew, Alia Ayesha and Sati Gopinath

Departments ofNuclear Medicine and Obstetrics and Gynecology, Faculty of Medicine, Kuwait University; Kuwait Central Radiopharmacy, Kuwait Cancer Control Center, Kuwait

Correspondence: For correspondence or reprints contact: Azu Owunwanne, PhD, Department of Nuclear Medicine, Faculty of Methane, P.O. Box24923, Safat 13110, Kuwait.

ABSTRACT

Placental binding and transfer of 99mTc d, 1-hexamethyl propyleneamine oxime (HMPAO) was studied in vitro using human placenta and pregnant guinea pigs. Materials and Methods: Five pieces of human placenta were incubated in 50 ml Earle's solution containing 1.85 MBq 99mTc d, 1-HMPAO. The percent binding of the tracer to the placenta per 1 ml standard solution was calculated. Pregnant guinea pigs representing first, second and third trimesters were each injected with 74 MBq 99mTc d, 1-HMPAO through the jugular or femoral vein after sedation was induced with pentabarbital sodium. Static images were obtained, the guinea pigs were killed, and the fetuses were removed, weighed and imaged separately. The placentas, maternal and fetal brains, lungs, livers and kidneys also were removed, and the radioactMty was assayed in a dose calibrator for each organ. The percent radioactivityin each organ was calculated. Results: The binding of 99mTc d, 1-HMPAO to human placenta ranged from 2.95% ± 1.5% to 5.82% ± 0.3% per 1 ml standard solution. Both the binding of 99mTc d, 1-HMPAO to guinea pig placenta and its transfer to the fetus increased with gestational age. The percent binding ranged from 0.09% ± 0.06% to 0.43% ± 0.05%, whereas that of transfer to the fetus ranged from 0.05% ± 0.03% to 2.19% ± 0.64%. Of the amount transfered to the fetus, the order of accumulation in the fetal organs was liver > blood>> brain > lungs > kidneys > heart. Conclusion: Technetium-99m d, 1-HMPAO binds to the placenta, and a minimal amount crosses the placental barrier and is transfered into the fetal circulation, mostly in the liver but a measurable amount is found in brain tissue.

Key Words: technetium-99m d, 1-hexamethyl propyleneamine oxime • placental binding • transfer • guinea pigs







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1998 by the Society of Nuclear Medicine.